公开(公告)号：US20110230467A1

公开(公告)日：2011-09-22

申请号：US13130527

申请日：2009-11-20

申请人： Shohei Shirakami ,  Fumie Takahashi ,  Yutaka Nakajima ,  Hirofumi Omura ,  Naohiro Aoyama ,  Hiroshi Sasaki ,  Takeshi Hondo ,  Hiroaki Tominaga

发明人： Shohei Shirakami ,  Fumie Takahashi ,  Yutaka Nakajima ,  Hirofumi Omura ,  Naohiro Aoyama ,  Hiroshi Sasaki ,  Takeshi Hondo ,  Hiroaki Tominaga

IPC分类号： A61K31/55 ,  A61K31/5513 ,  A61K31/5377 ,  A61P43/00 ,  A61K31/497 ,  A61K31/506 ,  A61K31/444 ,  A61K31/4439 ,  C07D401/14 ,  C07D413/14 ,  C07D401/12 ,  C07D417/14 ,  C07D409/14 ,  C07D401/00

CPC分类号： C07D401/12 ,  C07D213/82 ,  C07D401/14 ,  C07D405/12 ,  C07D409/14 ,  C07D413/12 ,  C07D413/14 ,  C07D417/14 ,  C07D471/10

摘要： [Problem] The present invention provides a 4,6-diaminonicotinamide compound which is useful as an active ingredient of a pharmaceutical composition, in particular, a pharmaceutical composition for treating diseases caused by undesirable and/or abnormal cytokine signal transduction.[Means for Solution] The present inventors have extensively studied compounds having a JAK3 inhibitory action, and as a result, they have found that a 4,6-diaminonicotinamide compound which is the compound of the present invention has an excellent JAK3 inhibitory action and is useful as an agent for preventing or treating diseases caused by undesirable and/or abnormal cytokine signal transduction, thereby completing the present invention.

摘要翻译： 本发明提供了可用作药物组合物的活性成分的特征的4,6-二氨基烟酰胺化合物，特别是用于治疗由不希望的和/或异常的细胞因子信号转导引起的疾病的药物组合物。 [解决方案]本发明人广泛研究了具有JAK3抑制作用的化合物，结果发现作为本发明化合物的4,6-二氨基烟酰胺化合物具有优异的JAK3抑制作用， 可用作预防或治疗由不良和/或异常细胞因子信号转导引起的疾病的药剂，从而完成本发明。